Michael Partridge | Senior Vice President, Investor Relations |
Jeff Leiden | Chairman and Chief Executive Officer |
Stuart Arbuckle | Chief Commercial Officer |
Paul Silva | Interim Chief Financial Officer |
Reshma Kewalramani | Chief Medical Officer |
Michael Yee | Jefferies |
Geoffrey Porges | Leerink |
Phil Nadeau | Cowen and Company |
Alethia Young | Cantor Fitzgerald |
Geoff Meacham | Barclays |
Paul Matteis | Stifel |
Terence Flynn | Goldman Sachs |
Robyn Karnauskas | Citi |
Brian Abrahams | RBC Capital Markets |
Matthew Harrison | Morgan Stanley |
Cory Kasimov | JPMorgan |
Hartaj Singh | Oppenheimer and Company |
Liisa Bayko | JMP Securities |
Welcome to the Vertex Full Year and Fourth Quarter 2018 Financial Results Conference Call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Tonight, we will review our continued efforts to develop new medicines for all people with cystic fibrosis, recent advances in our research and development pipeline, and our 2018 financial results and 2019 guidance. Making prepared remarks on the call tonight, we have Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer and I would like to welcome to the call Paul Silva, Vertex’s Interim Chief Financial Officer.